Top

Published in:

Open Access 01-03-2018 | Special Article

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts

Author: Matti Aapro

Published in: Supportive Care in Cancer | Special Issue 1/2018

Excerpt

Significant progress has been made in the search for perfection regarding management of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. As our understanding of the physiologic aspects of this complex side effect expands, new targets and novel antiemetic therapies will continue to emerge. The substantial gains achieved with the introduction of 5-hydroxytryptamine (5-HT3) and neurokinin-1 (NK-1) receptor antagonists provide evidence that these physiologic insights can be translated into active therapies that improve patient care [1]. …

Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefPubMed

Roila F, Molassiotis A, Herrstedt J, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119-v133. Available at: https://doi.org/10.1093/annonc/mdw270

National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Antiemesis Version 2.2017. Available at: www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 30 May 2017

Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261CrossRefPubMed

Costa AL, Abreu C, Pacheco TR et al (2015) Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumors. Biomed Res Int 2015:309601PubMedPubMedCentral

Cardoso F, Colleoni M, Di Leo A et al (2016) Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treat Comm 6:S1–S10CrossRef

Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J (2018) Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol 2018 Jan 10

Doggrell SA (2017) Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV)—is there still a role after comparison with palonosetron? Expert Opin Pharmacother 18:1019–1026CrossRefPubMed

Fosaprepitant dimeglumine [prescribing information]; Merck Sharp & Dohme Corp: Whitehouse Station. 2017. Available at: https://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_pi.pdf. Accessed: 30 May 2017

10.

TESARA Announces Updates to the U.S. prescribing information for VARUBI® (rolapitant) injectable emulsion. [Press release]. Available at: ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-updates-us-prescribing-information-varubir. Accessed: 16 Jan 2018

11.

Aprepitant injectable emulsion [prescribing information]. Heron Therapeutics, Inc: San Diego. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209296s000lbl.pdf. Accessed: January 10, 2018

12.

Netupitant and palonosetron [prescribing information]; Helsinn Therapeutics: Iselin. 2016. Available at: https://www.akynzeo.com/assets/pdf/Prescribing_Information.pdf. Accessed: 30 May 2017

13.

Rolapitant [prescribing information]; Tesaro, Inc: Waltham. 2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206500s000lbl.pdf. Accessed: 30 May 2017

14.

Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142CrossRefPubMedPubMedCentral

15.

National Institutes of Health. Clinicaltrials.gov. [Website]. Available at: clinicaltrials.gov. Accessed: 18 Jan 2018

16.

Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576–583CrossRefPubMedPubMedCentral

17.

Janelsins MC, Tejani M, Kamen C et al (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14:757–766CrossRefPubMedPubMedCentral

18.

Ng T, Mazzarello S, Wang Z et al (2016) Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 155:337–344CrossRefPubMed

19.

Grunberg SM, Slusher B, Rugo HS (2013) Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 11:1–18PubMed

20.

Dranitsaris G, Molassiotis A, Clemons M et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260–1267CrossRefPubMedPubMedCentral

21.

Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308CrossRefPubMed

Title: Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
Author: Matti Aapro
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue Special Issue 1/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4121-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2018

Guidelines versus individualized care for the management of CINV

Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information

CINV: still troubling patients after all these years

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction

Getting it right the first time: recent progress in optimizing antiemetic usage

Keynote webinar | Spotlight on antibody–drug conjugates in cancer